TOC
How Kos Pharmaceuticals turned a 50-year-old drug for raising HDL cholesterol into a brand-new, burgeoning business.
How Kos Pharmaceuticals turned a 50-year-old drug for raising HDL cholesterol into a brand-new, burgeoning business.
68
Features
Global Pricing
The Cost of Innovation
Highlights from "Large Molecules, Large Dreams," a conference at MIT's Sloan School of Management
Drugs are expensive in some countries and cheaper in other. And that, say experts, is a situation that benefits not just companies, but patients.
54
Sales Training
It's All in the Details
Hossam Sadek and Zach Henderson IMS Health
Once you've collected unprecedented amounts of data, how do you make the information more useful to reps? Hint: Less really is more.
78
Lifecycle Management
The Big Squeeze
Terry Hisey
Capgemini
Everybody talks about lifecycle management, but hardly anyone seems to get the real point: It's not just about sales, it's about profits.
86
Marketing
New Horizons in Pharmaceutical Managed-Care Marketing
Ira Studin
Stellar Managed Care ConsultingThe landscape is changing. Here's what it means to your formulary marketing efforts.
100
Strategies
Winning Combinations
Allan Fine
Navigant Consulting
They're cheaper to develop, they reduce risks for companies, and they save money for patients. No wonder pharma increasingly is turning to combo drugs.
114
News & Analysis
Leading Indicators
News
FDA issuing more warning letters
- Maryland county helps residents buy drugs from Canada
- Novartis backs rules for follow-up protein product development
- Experts say an HIV/AIDS vaccine is still years away
- Critics fear new privacy rule will affect access to research.
21
Data
Why doctors see reps
- Who consumers trust
- Assessing pharma's political contributions.
32
Thought Leaders
Acambis' Gordon Cameron explains the pluses and minuses of Project BioShield.
36
Washington Report
As Congress debates greater transparency for clinical trials, watch out for threats to pediatric exclusivity.
Jill Wechsler
42
Global Report
Counterfeit drugs appear in the British supply chain, and the government sends pharma a message.
Sarah Houlton
42
Leadership
Winning isn't always the only thing. Sometimes, you should just walk away.
Sander A. Flaum
Flaum Partners
48
Legal Forum
Generic concerns: Some licensing agreements are in violation of antitrust law. But how can you tell?
Bryan Schaefer
Alston & Bird
52
Strategy & Tactics
Direct to Consumer
Want lifetime customers? Invest in a compliance strategy that changes along with patients' relationship with the brand.
Dorothy L. Smith, PharmD
The Consumer Information Corporation
127
Marketing to Professionals
PDR turns 60 and recounts its long and illustrious history.
140
Sales Management
Mergers and acquisitions wreak havoc on reps' productivity—but incentives help.
144
Alternative Media
Blogs helped Howard Dean get on the map. Can they help pharma?
Debrianna Obara
i-Frontier
132
Public Relations
Advocacy-based PR builds long-term support for brands that your DTC dollars can't buy.
Josh Weinstein
iwEinstein Strategic Messaging
136
Insights
From the Editor
Pharma's most important product? Let's hear it for out-of-patent drugs.
Patrick Clinton
Editor-in-Chief
14
Back Page
Political influence today guarantees nothing tomorrow.
Lance E. Lindblom
Nathan Cummings Foundation
154
Resources
People Update
147
Calendar of Events
150
Advertisers Index
148
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
